TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tamada, Taro ^a   Shinmi, Daisuke ^b   Ikeda, Masahiro ^b   Yonezawa, Yasushi ^a   Kataoka, Shiro ^b   Kuroki, Ryota ^a   Mori, Eiji ^b   Motoki, Kazuhiro ^b  

^a JAPAN ATOMIC ENERGY AGENCY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MULTIPROTEIN COMPLEX; PROTEIN BINDING; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

AGONISTS; ANIMAL; APOPTOSIS; BINDING SITE; CELL SURVIVAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HAMSTER; HUMAN; METABOLISM; MISSENSE MUTATION; MOLECULAR MODEL; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; STEREOISOMERISM; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; MUTATION, MISSENSE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; STEREOISOMERISM;

EID: 84950279918     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17936     Document Type: Article

References (39)

1. Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995).
2. Pitti, R. M. et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690 (1996).
3. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157-163 (1999).
4. Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162 (1999).
5. Pan, G. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113 (1997).
6. Walczak, H. et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16, 5386-5397 (1997).
7. Chaudhary, P. M. et al. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7, 821-830 (1997).
8. Screaton, G. R. et al. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7, 693-696 (1997).
9. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2, 420-430 (2002).
10. LeBlanc, H. N. & Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66-75 (2003).
11. Mongkolsapaya, J. et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol. 6, 1048-1053 (1999).
12. Hymowitz, S. G. et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4, 563-571 (1999).
13. Cha, S. S. et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275, 31171-31177 (2000).
14. Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 281, 1305-1308 (1998).
15. Graves, J. D. et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 26, 177-189 (2014).
16. Nemčovičová, I., Benedict, C. A. & Zajonc, D. M. Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions. PLoS Pathog. 9, e1003224 (2013).
17. Fellouse, F. A. et al. Molecular recognition by a binary code. J. Mol. Biol. 348, 1153-1162 (2005).
18. Li, B. et al. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J. Mol. Biol. 361, 522-536 (2006).
19. Adams, C. et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 15, 751-761 (2008).
20. Griffith, T. S. et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162, 2597-2605 (1999).
21. Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891-4898 (2001).
22. Ishida, I. et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 4, 91-102 (2002).
23. Mori, E. et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ. 11, 203-207 (2004).
24. Motoki, K. et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res. 11, 3126-3135 (2005).
25. Nagane, M., Shimizu, S., Mori, E., Kataoka, S. & Shiokawa, Y. Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro. Oncol. 12, 687-700 (2010).
26. Tamada, T. et al. Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex. Proc. Natl. Acad. Sci. USA 103, 3135-3140 (2006).
27. Chan, F. K. et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354 (2000).
28. Siegel, R. M. et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354-2357 (2000).
29. Clancy, L. et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 102, 18099-18104 (2005).
30. Mukai, Y. et al. Solution of the structure of the TNF-TNFR2 complex. Sci. Signal. 3, ra83 (2010).
31. Naismith, J. H., Devine, T. Q., Brandhuber, B. J. & Sprang, S. R. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J. Biol. Chem. 270, 13303-13307 (1995).
32. Scott, F. L. et al. The Fas-FADD death domain complex structure unravels signaling by receptor clustering. Nature 457, 1019-1022 (2009).
33. Wang, L. et al. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct. Mol. Biol. 17, 1324-1330 (2010).
34. Otwinoski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
35. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C. & Read, R. J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D 61, 458-464 (2005).
36. Saphire, E. O. et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155-1159 (2001).
37. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
38. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D53, 240-255 (1997).
39. Harris, L. J., Larson, S. B., Hasel, K. W. & McPherson, A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36, 1581-97 (1997).